CAR T-Cell Therapy for Multiple Myeloma

Chimeric antigen receptor, or CAR, T-cell therapy is a form of immunotherapy that uses a patient’s own immune system to fight myeloma. The process starts by putting a patient’s blood through a blood processing system that separates t-cells from the rest of the blood. The t-cells are then taken to a lab where they’re modified to produce the CAR proteins needed to recognize, target and fight tumor cells. The new cells are refined in the lab before introducing them back into the patient’s body so they can multiply and work on attacking the myeloma cells.